Heron Therapeutics (HRTX) Sinks as 3 Key Execs Resign

October 3, 2016 10:12 AM EDT
Get Alerts HRTX Hot Sheet
Trade HRTX Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Heron Therapeutics (NASDAQ: HRTX) is under heavy pressure Monday (-10.6%) after the company disclosed late Friday it has accepted the resignations of Neil J. Clendeninn, M.D., Ph.D., the Company’s Senior Vice President, Chief Medical Officer, Paul G. Marshall, the Company’s Senior Vice President, Technical Operations, and Brian G. Drazba, the Company’s Vice President, Finance and Chief Financial Officer. The resignations of Dr. Clendeninn and Mr. Marshall are effective as of September 30, 2016.

Heron said they will each be eligible to receive a one-time severance payment equal to their respective 2016 annual salary, plus the 2016 annual bonus payment for Dr. Clendeninn and the average annual bonus paid over the prior three years for Mr. Marshall, and certain additional severance benefits.

The resignation of Mr. Drazba will be effective as of March 31, 2017, at which time he will be eligible to receive a one-time severance payment equal to his 2016 annual salary and his average annual bonus paid over the prior three years, as well as certain additional severance benefits.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Hot Mgmt Changes, Management Changes

Add Your Comment